Biography for Mark Hollmer
Mark Hollmer, Editor
Mark Hollmer is a veteran life sciences journalist. Before joining FierceMarkets, he was a staff writer for "The Gray Sheet," an Elsevier Business Intelligence publication, where he wrote about medical device and diagnostics startups, and regulatory milestones for large companies in both sectors, among other topics. Previously, he spent several years as a life sciences and health care reporter at the Boston Business Journal, where he followed the biotechnology, medical devices, hospital and health insurance industries. While there, he spoke regularly about top life sciences stories during appearances on New England Cable News, and commented on the growth of the Bay State's life sciences industry as part of a special that aired on the WGBH Boston public television station. Separately, he served a stint at Brown University, promoting innovations generated by the school's life sciences researchers and medical school. Mark lives with his partner in Washington, D.C. where he enjoys the region's multiple museums, great restaurants and excellent cultural scene.
Articles by Mark Hollmer
Focal Therapeutics is working to address the idea of targeted breast cancer therapy in a way that drug companies don't. The California outfit markets a 3-D tissue marker designed to help surgeons spot the precise site for tumor removal and subsequent delivery of radiation treatment.
Aptar Pharma has taken a major leap beyond spray pumps and inhalers. At a major November conference, it debuted prefilled, auto-injectable drug delivery technology designed to help it attract more biopharmaceutical clients.
A self-assembling material could enable the improved delivery of everything from vaccines, to treatments for cancer, cardiovascular disease and neurological conditions, University of Melbourne researchers have determined.
York University students in the U.K. are developing a nanoparticle cancer treatment delivered through a patch, and they're turning to crowdfunding to raise money for their research.
Acorda Therapeutics is paying at least $8 million for two neuropathic pain drugs from NeurogesX. The deal adds patch and topical liquid treatments to the company's offerings.
Less than two months after getting the FDA go-ahead, Oramed Pharmaceuticals has enrolled the first patient in a Phase IIa trial for its oral insulin pill. The milestone apparently places it in the lead among companies trying to be the first to market with such a product.
The European injectable drug delivery technologies market was already worth a substantial $6.8 billion in 2012. But that number should soar to $12.4 billion by 2017, Markets and Markets estimates in a new report.
With an increasing reliance on nanoparticles to deliver intravenous drug treatments and serve as imaging agents, how do you make sure they are powerful enough to reach their target? The answer: math.
You've heard about China and India becoming increasingly significant locales in the Asia-Pacific region for conducting biotechnology research and drug development. Australia, not so much.
This year we're naming Fierce's 5 Drug Delivery Companies to Watch. All are making their mark by bringing drug delivery technology into everyday medical device and pharmaceutical use.